TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38523332
Drug: Ad26.ZEBOV, MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses from three consecutively manufactured lots)
Study: 38523907
Drug: Multi-module music
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-module music therapy group (rhythm-guided walking and singing training)
Study: 38523907
Drug: Multi-module music
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-module music therapy group
Study: 38524266
Drug: Treatment-as-usual group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual group (TAU)
Study: 38524688
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive sacroiliac posterior fusion LinQ allograft implant
Study: 38524849
Drug: Immediate pressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate pressor response to oral salt (IPROS)
Study: 38525605
Drug: Non-MRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MRA treatment
Study: 38525699
Drug: Nurse-Implemented Music
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-Implemented Music Therapy intervention (structured over five weeks with ten 1-hour sessions, twice weekly)
Study: 38525699
Drug: Nurse-Implemented Music
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-Implemented Music Therapy intervention
Study: 38526047
Drug: AT-752 single
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-752 single dose up to 1,500 mg
Study: 38526047
Drug: AT-752 multiple
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-752 multiple doses up to 750 mg three times daily (TID)
Study: 38526047
Drug: AT-752 750
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-752 750 mg TID
Study: 38526054
Drug: mRNA-1647 vaccine
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1647 vaccine (three-dose series)
Study: 38526461
Drug: Nonspecific Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific Oral Migraine Preventives (OMPMs)
Study: 38526612
Drug: Oxybutynin, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin, a muscarinic receptor antagonist, dosage and duration not specified
Study: 38526764
Drug: NSE (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSE (same exercises performed twice a week at a physiotherapy clinic for 3 months)
Study: 38526910
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group C)
Study: 38527605
Drug: Top 3
Normalized name: Nimotop 30mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top 3 'more accurate' treatment success definitions (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score ≤5, Urogenital Distress Inventory-6 score ≤33.3, no/mild stress urinary incontinence response on Urogenital Distress Inventory-6 question 3)
Study: 38527849
Drug: Pascolizumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pascolizumab 2.5 mg/kg
Study: 38527849
Drug: Pascolizumab 10
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pascolizumab 10 mg/kg
Study: 38527849
Drug: Pascolizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pascolizumab (both doses)
Study: 38528164
Drug: novel radiolabelled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: novel radiolabelled somatostatin receptor antagonist
Study: 38528445
Drug: investigator choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigator choice standard therapy (ICT)
Study: 38528456
Drug: Online adaptive
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online adaptive radiotherapy (oART) with daily automated treatment re-planning
Study: 38528476
Drug: Lasmiditan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (various doses)
Study: 38528476
Drug: Lasmiditan (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (dose adjustments)
Study: 38529674
Drug: Deucravacitinib 12
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 12 mg QD
Study: 38530160
Drug: Letrozole (LTZ)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LTZ) 15 mg daily
Study: 38530213
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy following peri-implantitis treatment (SPIT)
Study: 38530213
Drug: Comprehensive information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive information provided prior to peri-implantitis treatment
Study: 38530474
Drug: 0.454% stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.454% stannous fluoride-containing dentifrice twice daily (test group, n=66)
Study: 38530474
Drug: 5.0% calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0% calcium sodium phosphosilicate-containing dentifrice twice daily (positive control group, n=64)
Study: 38530474
Drug: 1150 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1150 ppm NaF dentifrice twice daily (negative control group, n=67)
Study: 38530565
Drug: epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (cisplatin plus pemetrexed, non-squamous)
Study: 38530565
Drug: epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus pemetrexed, non-squamous)
Study: 38530565
Drug: epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus paclitaxel, squamous or non-squamous)
Study: 38530565
Drug: epacadostat plus
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat plus pembrolizumab and chemotherapy
Study: 38530569
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) followed by brachytherapy
Study: 38530569
Drug: Initial tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial tumor volume (iTV) > 55.99 cc
Study: 38530569
Drug: Restaging tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restaging tumor volume (rTV) > 6.25 cc
Study: 38531002
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily for 52 weeks
Study: 38531362
Drug: Three-dimensional optoacoustic
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional optoacoustic imaging in patients who received disease-modifying therapy
Study: 38531570
Drug: Precision dosing
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision dosing of infliximab with a clinical decision support tool (RoadMAB) targeting specific trough concentrations and pharmacodynamic targets.
Study: 38531570
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care dosing of infliximab with a modified starting dose (5 or 7.5 mg/kg based on pretreatment serum albumin) aiming for maintenance trough concentrations of 5-10 µg/mL.
Study: 38531585
Drug: Insulin Pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Pump Therapy (IPT)
Study: 38531585
Drug: Insulin Pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Pump Therapy (IPT) with BGM
Study: 38531585
Drug: Insulin Pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Pump Therapy (IPT) with CGM
Study: 38531939
Drug: Ultra-low-dose computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose computed tomography (ULD-CT)
Study: 38531939
Drug: Surgery or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery or stereotactic body radiation therapy (SBRT)
Study: 38532251
Drug: Text-message intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Text-message intervention combining cognitive-behavioural therapy (CBT) texts with techniques from cognitive psychology (message framing) and social psychology (growth mindsets).
Study: 38532395
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine
Study: 38532395
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx)
Study: 38532451
Drug: Moderate- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate- to vigorous-intensity physical activities combined with low-dose PK-guided EHL FVIII prophylaxis for 6 months
Study: 38532503
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (amoxicillin 500 mg/clavulanic acid 125 mg) given after delivery
Study: 38532768
Drug: Inhaled imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled imatinib (AV-101)
Study: 38533127
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with one to two doses
Study: 38533127
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with three or more doses
Study: 38533552
Drug: Ulotaront (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulotaront (150 mg)
Study: 38533552
Drug: Previous antipsychotic
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous antipsychotic (PA)
Study: 38533643
Drug: Ketone ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone ester (KE) treatment for 14 days
Study: 38533985
Drug: No TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TNF inhibitors (Control)
Study: 38535011
Drug: Low-dose non-contrast
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose non-contrast thoracic CT
Study: 38536082
Drug: Enzalutamide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (120 mg/d) + Relacorilant (escalating doses, RP2D of 150 mg/d)
Study: 38536128
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day nicotinamide
Study: 38536227
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable (LAI) HIV antiretroviral therapy (ART)
Study: 38536227
Drug: Patient-oriented tools
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-oriented tools for comparing LAI ART and daily oral ART options
Study: 38536442
Drug: HEV-239 (Hecolin)
Normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly on days 1, 29, and 180
Study: 38536442
Drug: HEV-239 (Hecolin)
Normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly
Study: 38536442
Drug: HEV-239 (Hecolin)
Normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV-239 (Hecolin) vaccine
Study: 38536545
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous sedation (control)
Study: 38536810
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous infusion of dual bNAbs (VRCO1LS and 10-1074)
Study: 38536994
Drug: intra-mucosal injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-mucosal injection of injectable platelet-rich fibrin (i-PRF)
Study: 38536994
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (Control)
Study: 38537155
Drug: Giredestrant (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant (30 mg oral once daily)
Study: 38537155
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of endocrine monotherapy (PCET)
Study: 38537255
Drug: Adjuvanted 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 3.75 μg + AS03/2017 doses with delayed boost interval
Study: 38537255
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of A(H7N9) IIV
Study: 38537255
Drug: Adjuvanted second
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted second dose with longer interval
Study: 38537255
Drug: AS03 adjuvant
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 adjuvant with second H7N9 IIV dose and extended boost interval to 4 months
Study: 38537270
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (32 g)
Study: 38537270
Drug: Plant protein
Normalized name: Kindersprout Plant Protein Chocolate Shake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant protein blend (32 g)
Study: 38537315
Drug: Nivolumab (anti-PD1)
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (anti-PD1) administered intravenously until end of treatment (12 months), progression, unacceptable toxicity, or death.
Study: 38537636
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) plus standard HFrEF treatment
Study: 38537636
Drug: Standard HFrEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HFrEF therapy alone
Study: 38537676
Drug: Fesomersen 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesomersen 40 mg
Study: 38537676
Drug: Fesomersen 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesomersen 80 mg
Study: 38537676
Drug: Fesomersen 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesomersen 120 mg
Study: 38537676
Drug: Fesomersen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesomersen (all doses pooled)
Study: 38537676
Drug: Fesomersen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesomersen (all doses)
Study: 38537773
Drug: OH2 oncolytic
Normalized name: OH2 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: OH2 oncolytic viral therapy derived from herpes simplex virus 2 (HSV-2)
Study: 38538057
Drug: Rescue intracranial
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue intracranial stenting (RIS) + best medical treatment (BMT)
Study: 38538093
Drug: SNK01 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNK01 in combination with gemcitabine/carboplatin (n=6)
Study: 38538093
Drug: SNK01 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNK01 in combination with cetuximab/gemcitabine/carboplatin (n=6)
Study: 38538093
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (SNK01 + chemotherapy/cetuximab)
Study: 38538161
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir or rilpivirine injections
Study: 38538867
Drug: Therapeutic vaccine
Normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations, combined with immune checkpoint inhibitors ipilimumab and nivolumab.
Study: 38538867
Drug: Therapeutic vaccine
Normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccine regimen (ChAd68 and samRNA) combined with immune checkpoint inhibitors.
Study: 38539462
Drug: Composite intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite intervention consisting of non-hormonal pharmacotherapy, digital cognitive behavioral therapy for insomnia (dCBT-I) using Sleepio, self-management strategies via myPatientSpace mobile application, and nomination of an additional support person/partner
Study: 38539914
Drug: Cosmetic treatment
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic treatment (cavitation peeling and sonophoresis with a commercial capillary repair serum)
Study: 38540138
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice a day for 4 weeks
Study: 38540555
Drug: Mood Lifters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood Lifters (ML) program
Study: 38543926
Drug: Aerosolized Ad5-nCoV
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized Ad5-nCoV (Low-Dose)
Study: 38543926
Drug: Intramuscular Ad5-nCoV
Normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Ad5-nCoV (Low-Dose)
Study: 38543926
Drug: Intramuscular-Aerosolized Ad5-nCoV
Normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular-Aerosolized Ad5-nCoV (Low-Dose)
Study: 38544798
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (GLP-1 receptor agonist + supervised exercise)
Study: 38544834
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with chemotherapy plus trastuzumab for breast cancer patients
Study: 38545090
Drug: BIO101 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIO101 (350 mg BID)
Study: 38545092
Drug: VBI-S (phospholipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-S (phospholipid nanoparticles) administered intravenously as boluses of 100 ml, 200 ml, 400 ml, and 800 ml until MAP goal was reached.
Study: 38545092
Drug: VBI-S (phospholipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-S (phospholipid nanoparticles) administered intravenously.
Study: 38545762
Drug: Daily Ecological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Ecological Momentary Assessments of Pain and Ability to Work
Study: 38546375
Drug: Orelabrutinib, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib, dosage and duration not available
Study: 38546803
Drug: Crisaborole QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole QD (once daily)
Study: 38546821
Drug: 5-day fasting-mimicking
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day fasting-mimicking diet (FMD) programme, monthly cycles as an adjunct to regular care
Study: 38546829
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film (SL-APO)
Study: 38546944
Drug: EGFR-Erbitux receptor
Normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone
Study: 38546960
Drug: Zanubrutinib (Bruton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib (Bruton tyrosine kinase inhibitor)
Study: 38547003
Drug: liso-cel (CAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: liso-cel (CAR T cell therapy)
Study: 38547135
Drug: Prolonged daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged daily motion modulated stimulation with a multichannel vestibulocochlear implant (VCI) prototype
Study: 38547322
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (20 mg/ml, 1 ml)
Study: 38547322
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride, 1 ml)
Study: 38547892
Drug: Gedatolisib plus
Normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gedatolisib plus palbociclib and endocrine therapy (Letrozole for group A, Fulvestrant for groups B-D)
Study: 38547892
Drug: Gedatolisib plus
Normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gedatolisib plus palbociclib and endocrine therapy
Study: 38547892
Drug: Treatment-related serious
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related serious adverse events
Study: 38547891
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 6.4 mg/kg (cohort 1)
Study: 38547891
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 5.4 mg/kg (cohort 1A)
Study: 38547893
Drug: LOAd703 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOAd703 combined with nab-paclitaxel (125 mg/m2) and gemcitabine